03 - Sağlık ve Kaliteli Yaşam

Goal:
03 - Sağlık ve Kaliteli Yaşam

Description

AMAÇ 3: SAĞLIKLI BİREYLER Çocuk ölüm oranlarının azaltılması, anne sağlığının iyileştirilmesi, HIV/AIDS, sıtma ve diğer hastalıklar ile mücadelede büyük aşama kaydetmiş durumdayız. 1990 yılından bu yana, önlenebilir çocuk ölümlerinde dünya genelinde %50’yi aşan azalma olmuştur. Anne ölümleri de dünya genelinde %45 azalmıştır. 2000 ile 2013 arasında HIV/AIDS bulaşma oranı %30 azalmış, 6,2 milyonu aşkın insan sıtmadan kurtarılmıştır. Bu ölümler; önleme ve tedavi, eğitim, aşı kampanyaları, cinsel ve üreme sağlığı hizmetleri vasıtasıyla önlenebilir. Sürdürülebilir Kalkınma Amaçları; AIDS, verem, sıtma ve diğer bulaşıcı hastalık salgınlarını 2030 yılına kadar ortadan kaldırmaya yönelik cesur bir taahhüttür. Amaç, herkesin genel sağlık hizmeti, güvenli ve erişilebilir ilaç ve aşıya kavuşmasını sağlamaktır. Aşı araştırma ve geliştirmelerinin desteklenmesi, bu sürecin vazgeçilmez bir parçasıdır.

Full item page

Publication Search Results

Now showing 1 - 8 of 8

Open Access
New Diagnosis Diabetes and Deep Venous Thrombosis with Glucagonoma Cases; Case Report
(2019-10-01T00:00:00Z) KARATOPRAK, CUMALİ; Karaaslan, Tahsin; KARAASLAN, TAHSİN; KARATOPRAK, CUMALİ
Glucagonomas; is a rare neuroendocrine tumor originating from alpha cells of the pancreas. Glucagonoma syndrome is a paraneoplastic entity known as diarrhea, weight loss, stomatitis, thrombosis, diabetes, and necrotizing migratory erythema. It is difficult to come to mind in the differential diagnosis with the very rarely seen and little known reason. We also wanted to present a patient with bilateral deep vein thrombosis and a new diagnosis of diabetes that we were difficult to diagnose.
Open Access
Vildagliptin Treatment on the Portal Venous Pressure and Hepatosteatosis in Patients with Type 2 Diabetes Mellitus
(2018-01-01) Kilicarslan, Rukiye; Cakirca, MUSTAFA; Aydin, SİNEM; OZKAN, Tuba; KOCAMAN, Orhan; Yolbas, Servet; Zorlu, MEHMET; Karatoprak, CUMALİ; Kiskac, MUHARREM; CIKRIKCIOGLU, Mehmet Ali; ERKOC, Reha; KARATOPRAK, CUMALİ; ÇAKIRCA, MUSTAFA; AYDIN, SİNEM; ZORLU, MEHMET; KISKAÇ, MUHARREM
Objective: This study investigated how vildagliptin (a di-peptidyl peptidase 4 inhibitor) affects portal vein pressure and hepatosteatosis in patients with type 2 diabetes mellitus.
Open Access
The relationship between the atherosclerotic cardiovascular disease risk score used in the prediction of cardiovascular disease risk and endocan.
(2019-05-01T00:00:00Z) Cakirca, M; Tunc, M; Zorlu, M; Dae, SA; Kiskac, M; Karatoprak, CUMALİ; ÇAKIRCA, MUSTAFA; ZORLU, MEHMET; TUNÇ, MUHAMMED; KARATOPRAK, CUMALİ
Objective: To date, there have been no studies investigating whether or not there is a correlation between the serum endocan level and the atherosclerotic cardiovascular disease (ASCVD) risk score that is frequently used in the determination of the risk of cardiovascular disease. If a single parameter such as endocan can provide reliable results which could be used in the prediction of the cardiovascular disease risk, the workload of the clinician would be lightened. The aim of this study was to investigate whether or not there is an association between the serum endocan level and the ASVCD risk score. Materials and methods: This prospective, cross-sectional study included individuals age 40-79 years with risk factors calculated using the ASVCD score and individuals without any of those risk factors. In accordance with ASCVD risk calculation, each participant was questioned with respect to age, gender, height, weight, and lifestyle habits such as smoking, diseases, and medications. Systolic blood pressure, diastolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and serum endocan levels were measured and recorded. The serum endocan levels and ASCVD scores were compared. Results: The study included 205 individuals, comprising 92 (44.9%) males and 113 (55.1%) females with a mean age of 50.7 ± 7.6 years. The 10-year atherosclerosis risk was determined as mean 6.32% ± 5.9% (range, 0.3%-27.3%). The mean serum endocan level was calculated as 1109.6 ± 1479.7 ng/mL. As the ASCVD risk score increased, no increase was detected in the serum endocan level. Conclusion: The results of the study suggested that the serum endocan level is not suitable for use in place of the ASCVD risk score as a predictor of cardiovascular disease risk.
Open Access
GAS6 intron 8 c.834 + 7G > A gene polymorphism in diabetic nephropathy.
(2015-06-01) ERKOÇ, R; ÇıKRıKÇıOĞLU, MA; AINTAB, E; TOPRAK, ALİ; KILIC, U; GOK, O; CETIN, AI; ZORLU, MEHMET; KıSKAÇ, MUHARREM; CAKIRCA, MUSTAFA; Karatoprak, CUMALİ; ISEN, HC; ZORLU, MEHMET; KISKAÇ, MUHARREM; ÇAKIRCA, MUSTAFA; KARATOPRAK, CUMALİ
Background - Aim: In animal experiments, growth arrest-specific 6 (Gas6) protein plays a key role in the development of mesangial cell and glomerular hypertrophy in the early phase of diabetic nephropathy, and diabetic nephropathy is prevented by warfarin-induced inhibition of GAS6 protein. It was shown that GAS6 intron 8 c.834+7G>A polymorphism is protective against type 2 diabetes mellitus, and AA genotype is associated with higher blood levels of GAS6 protein. Our aim is to investigate whether this polymorphism is a risk factor for diabetic nephropathy in type 2 diabetes mellitus. Method: Eighty-seven patients with diabetic nephropathy were compared with 66 non-diabetic controls in terms of GAS6 intron 8 c.834+7G>A polymorphism. Patients with history of stroke, ischemic heart disease were excluded. Each patient was examined by the ophthalmologist to determine diabetic retinopathy. Results: Frequency of GG, GA and AA genotypes are similar in diabetic nephropathy and control groups according to GAS6 intron 8 c.834+7G>A polymorphism (p = 0.837). Rate of diabetic retinopathy was 54.02%. In the subgroup analysis, GA genotype was significantly more frequent than GG genotype in patients with diabetic retinopathy when compared to without diabetic retinopathy (p = 0.010). Conclusion: In our study, GAS6 intron 8 c.834+7G>A polymorphism was not associated with diabetic nephropathy in type 2 diabetes mellitus. However, heterozygous state of this polymorphism may be a risk factor for diabetic retinopathy in patients with diabetic nephropathy.
Open Access
Effects of 18-month Vildagliptin Treatment on Portal Vein Pressure and Hepatosteatosis
(2019-10-01T00:00:00Z) KARATOPRAK, CUMALİ; KISKAÇ, MUHARREM; ZORLU, MEHMET; ÇAKIRCA, MUSTAFA; Aydin, Sinem; Ozkan, Tuba; KARATOPRAK, CUMALİ; ÇAKIRCA, MUSTAFA; ZORLU, MEHMET; KISKAÇ, MUHARREM
Objective: Patients with type 2 diabetes have an increased tendency to develop hepatosteatosis. The effects of drugs used to treat diabetes on the liver, regardless of the disease, are unknown.The aim of this study was to investigate the effects of vildagliptin, a dipeptidyl peptidase-4 inhibitor, on the portal vein pressure and hepatosteatosis in patients with type 2 diabetes in the 18 months of follow-up.
Open Access
The effects of long term fasting in Ramadan on glucose regulation in type 2 Diabetes Mellitus
(2013-09-01) YOLBAS, S.; CAKIRCA, MUSTAFA; CINAR, A.; ZORLU, MEHMET; KISKAC, MUHARREM; Karatoprak, CUMALİ; ERKOC, R.; TASAN, ERTUĞRUL; KARATOPRAK, CUMALİ; ÇAKIRCA, MUSTAFA; ZORLU, MEHMET; KISKAÇ, MUHARREM; TAŞAN, ERTUĞRUL
Introduction: For Ramadan fasting, observing Muslims do not eat or drink between sunrise and sunset during Ramadan, Islam's holy month of the year according to the lunar calendar. In 2011, fasting patients with diabetes fasted for an average of 16.5 hours per day, having 2 meals between sunset and sunrise for a month. We aimed to evaluate the impact of extended fasting on glucose regulation and observe possible complications of extended fasting in type 2 diabetes mellitus patients. Patients and methods: We conducted a randomized, retrospective, observational study. Patients who presented at the Diabetes Clinic during the 15 days before and after Ramadan in August 2011 Istanbul, whose hemoglobin A1c, fasting plasma glucose, postprandial plasma glucose, weight and height value examinations and follow-up were completed were included in the study. Findings: Seventy-six diabetes patients who fasted during Ramadan (fasting group) and 71 patients with diabetes who did not fast (non-fasting group) were included in the study. These two groups with similar demographic characteristics were compared before and after Ramadan. HbA1c, fasting and postprandial plasma glucose, body mass index, weight and adverse events were evaluated. No statistically significant difference was observed among the fasting and the non-fasting groups. There was no difference between the pre and post-Ramadan values of the fasting group. Conclusions: We could not find any negative effects of extended fasting on glucose regulation of patients with diabetes who are using certain medications. No serious adverse event was observed. We failed to demonstrate benefits of increasing the number of meals in patients with diabetes.
Open Access
Frequency and determinants of erectile dysfunction in Turkish diabetic men
(2015-03-01) Buyukaydin, BANU; KISKAC, MUHARREM; ZORLU, MEHMET; CAKIRCA, MUSTAFA; KARATOPRAK, CUMALİ; YAVUZ, Erdinc; KISKAÇ, MUHARREM; ZORLU, MEHMET; ÇAKIRCA, MUSTAFA; BÜYÜKAYDIN, BANU; KARATOPRAK, CUMALİ
Background: Erectile dysfunction (ED) or impotence is a sexual dysfunction characterized by the inability to develop or maintain an erection of the penis during sexual performance. ED is observed more frequently and manifests earlier in diabetic patients compared to the normal population. Material and Methods: One hundred and seventeen consecutive male type 2 diabetes patients seen in our Diabetes Outpatient Clinic were included in our study and these patients were evaluated in terms of the presence and duration of ED, treatment and response to treatment of ED, duration of diabetes mellitus, HbA1c levels, and the presence of microalbuminuria, estimated from 24‑hour urine collections. Results: The patients included in our study were divided into three groups: Patients with no ED, mild‑to‑moderate ED, and severe ED. Twenty‑nine patients (24.8%) fell in the no ED group, 28 (23.9%) in the mild‑to‑moderate ED group, and 60 (51.3%) in the severe ED group. There were statistically significant differences between these three groups in terms of age (P = 0.015) and duration of diabetes mellitus (P = 0.03). The groups were similar in terms of microalbuminuria measured from 24‑hour urine collections and HbA1c levels (P = 0.328 and P = 0.905, respectively). Twenty‑three of the 88 patients with ED (26.1%) were on ED treatment and 43.5% of these patients reported benefit from the therapy. Conclusion: Age and duration of diabetes were the main determinants of the presence and severity of ED in male Turkish type 2 diabetic patients. The HbA1c levels were higher in patients with ED, but the differences in levels between the groups did not reach statistical significance.
Open Access
Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients
(2014-01-01) Cakirca, MUSTAFA; Soysal, Pinar; Zorlu, MEHMET; Kiskac, MUHARREM; Kanat, Mustafa; CIKRIKCIOGLU, Mehmet Ali; Karatoprak, CUMALİ; HURSITOGLU, Mehmet; Camli, AHMET ADİL; ERKOC, Reha; ABDUL-GHANI, Muhammad; ÇAKIRCA, MUSTAFA; KARATOPRAK, CUMALİ; ZORLU, MEHMET; KISKAÇ, MUHARREM; SOYSAL, PINAR; ÇAMLI, AHMET ADİL
Aims: A close association has been demonstrated between increased cardiovascular risk and high asymmetric dimethylarginine (ADMA) levels in type 2 diabetes mellitus (DM) patients. We planned to measure serum ADMA levels in type 2 DM patients using vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Materials and methods: A total of 68 type 2 DM patients who were on metformin were enrolled in the study. Based on the glycemic levels of patients, vildagliptin was added on to treatment in 33 patients. Patients were followed for 6 months. Serum ADMA, C-reactive protein, and fibrinogen levels were compared in groups of patients using metformin or metformin + vildagliptin, after 6 months. Results: Serum ADMA levels were found to be significantly lower in the group using vildagliptin compared to the group using metformin + vildagliptin (P<0.001). However, serum C-reactive protein and fibrinogen levels were statistically similar in the two study groups (P=0.34 and P=0.23, respectively). Conclusion: Metformin + vildagliptin treatment was observed to lower serum ADMA levels in type 2 DM patients. Our findings notwithstanding, large-scale prospective randomized controlled studies are warranted to conclude that vildagliptin provides cardiovascular protection along with diabetes regulation. Keywords: asymmetric dimethylarginine (ADMA); dipeptidyl peptidase-4 (DPP-4) inhibitor; type 2 diabetes mellitus; vildagliptin.